The size of the Global Ovarian Cancer Therapeutics Market is predicted to register a CAGR of 10.1% from 2020 to 2025.
The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer remains undetected until the mutation spread to the stomach and pelvis, which is a very advanced stage of ovarian cancer, which is fatal. A substantial percentage of women are dying due to ovarian cancer across the world. Ovarian cancer shows any pious symptoms in the affected women, but they might experience pain in the abdomen, fatigue, indigestion, bloating, and nausea.
Key Market Drivers
The significant factors that are significantly boosting the growth of the global ovarian cancer therapeutics market are the rise in aged women's accounts and the increased prevalence of ovarian cancer across the world. The increasing economies of the countries in the developed and developing regions are leading to the expansion of healthcare. They are contributing to the growth of the global ovarian cancer therapeutics market.
Additionally, the increasing adoption rate of combination therapies for the treatment is another significant factor that catalyzes the growth of this market. Increased funding from governments and private organizations to research and develop effective treatment techniques and advanced therapeutics for treating ovarian cancer is boosting the worldwide ovarian cancer therapeutics market.
The healthcare industry is anticipated to witness the rise in the number of medical professionals at a significant rate, which is supposed to create lucrative growth opportunities for key market players in the global ovarian cancer therapeutics market over the forecast period world. Increasing demand for home care services and nurses due to an increased percentage of the aged population is likely to offer several growth opportunities for the market stakeholders.
Rising investments and funding from governments in the developed nations for the research and development activities to battles the ovarian cancer is suspected of creating growth opportunities for the key players functioning in the world's ovarian cancer therapeutics market.
The unavailability of adequate technology for detecting ovarian cancer in early stages is the major challenge limiting the growth of the global ovarian cancer therapeutics business. Lack of skilled professionals is challenging the key players for the growth of the market. Also, the lack of funding for research and development activities is challenging the growth of the ovarian cancer therapeutics industry.
Impact of COVID-19 pandemic on the global ovarian cancer therapeutics market
The COVID-19 pandemic has negatively affected many countries across the globe. Several measures introduced to deal with the pandemic, such as lockdowns, reduction in trade activities, and shutdown of multiple factories and workplaces in several countries, could save lives; however, these measures have wide-ranging economic effects inducing economic contagion. Along with the risk of a slowdown of global growth, the results of COVID-19 are adversely affecting various economic sectors in economies across the globe.
Key manufacturing segments have halted operations across the globe in response to the lockdown regulations issued by governments of various countries and discontinuing public transport services.
Amid the COVID-19 pandemic, the Ovarian Cancer Therapeutics Market is witnessing a significant change in operations.
Market Size Available
2019 to 2025
2020 to 2025
By Stage of Cancer, Diagnosis, Type of Treatment, Type of Cancer and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
This research report on the global ovarian cancer therapeutics market has been segmented and sub-segmented based on the stage of cancer, diagnosis, type of treatment, type of cancer, and region.
Ovarian Cancer Therapeutics Market - By Stage of Cancer:
Ovarian Cancer Therapeutics Market - By Cancer Type:
Based on the cancer type, the epithelial ovarian cancer segment is predicted to hold leading shares in the global market during the forecast period. The rising population and growing awareness over the availability of treatment procedures bolstered the demand for this market. Increasing incidences of ovarian cancer patients propel the growth rate of the ovarian low malignant potential tumor segment.
Ovarian Cancer Therapeutics Market - By Diagnosis:
Ovarian Cancer Therapeutics Market - By Type of Treatment:
Based on the type of treatment, Immunotherapy is dominating the market. It is presumed to grow at a high pace during the forecast period due to the continually increasing adoption rate of immunotherapy treatments and the expansion of healthcare, leading to the rise in the number of patients diagnosed with ovarian cancer undergoing immunotherapy.
The targeted therapy market is continuously increasing at a high rate of CAGR. It is likely to continue the trend during the forecast period due to the increasing popularity of targeted therapies and the rising prevalence of women affected by ovarian cancer.
Ovarian Cancer Therapeutics Market - By Region:
North America is dominating the Global Ovarian Cancer Therapeutics Market. It is assumed to continue the trend during the outlook period due to the increasing pervasiveness of ovarian cancer and the geriatric population's growing account. The United States controls the highest share in the ovarian cancer diagnostics and therapeutics market and has added significantly. Ovarian cancer is the ninth most common cancer and the fifth leading cause of cancer death among women in the United States. Furthermore, most of the top global ovarian cancer diagnostics players are based in the United States. It tends to be a significant advantage for the region, which is expected to drive the market.
Asia-Pacific demand is contributing a significant share of revenues to the market. It is likely to witness growth at high CAGR during the projection period due to the increasing prevalence of the aged population and the growing economies of countries such as China and India.
NOTABLE COMPANIES IN THE MARKET
Companies leading the global ovarian cancer therapeutics market profiled in the report are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen, Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Genentech Inc.
KEY MARKET RECENT HAPPENINGS:
GlaxoSmithKline plc has developed a novel drug for women diagnosed with advanced ovarian cancer. The company has applied for the approval of a drug called zejula to the FDA in February 2020; the FDA aims for the efficient reviewing process to make it available for the patients.
In the recent studies, the researchers have identified a new drug fragment; as per the reports published by the research team, the pieces can help analyze the function of cancer protein leading to the development of drugs in the future.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Stage Of Cancer
5.1.1 Stage I
5.1.2 Stage II
5.1.3 Stage III
5.1.4 Stage IV
5.1.5 Y-o-Y Growth Analysis, By Stage Of Cancer
5.1.6 Market Attractiveness Analysis, By Stage Of Cancer
5.1.7 Market Share Analysis, By Stage Of Cancer
5.2.2 Primary Peritoneal Carcinoma
5.2.3 Ovarian Stromal Tumors
5.2.4 Ovarian Germ Cell Tumors
5.2.5 Epithelial Ovarian Tumors
5.2.6 Y-o-Y Growth Analysis, By Type
5.2.7 Market Attractiveness Analysis, By Type
5.2.8 Market Share Analysis, By Type
5.3.2 Physical Examination
5.3.3 Blood Tests
5.3.6 CT Scan
5.3.8 Human Chorionic Gonadotropin Test
5.3.10 Y-o-Y Growth Analysis, By Diagnosis
5.3.11 Market Attractiveness Analysis, By Diagnosis
5.3.12 Market Share Analysis, By Diagnosis
5.4.3 Radiation Therapy
5.4.4 Hormonal Therapy
5.4.7 Targeted Therapy
5.4.8 Y-o-Y Growth Analysis, By Treatment
5.4.9 Market Attractiveness Analysis, By Treatment
5.4.10 Market Share Analysis, By Treatment
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.4 Market Attractiveness Analysis
6.1.5 Market Share Analysis
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Aetera Zenteris Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Eli Lilly and Company
8.5 Janssen Pharmaceuticals, Inc.
8.6 Bristol Myers Squibb Company
8.7 Novogen, Inc.
8.9 Boehringer Ingelheim
8.11 Genentech Inc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures